186 related articles for article (PubMed ID: 36471194)
21. Buprenorphine prescribing practice trends and attitudes among New York providers.
Kermack A; Flannery M; Tofighi B; McNeely J; Lee JD
J Subst Abuse Treat; 2017 Mar; 74():1-6. PubMed ID: 28132694
[TBL] [Abstract][Full Text] [Related]
22. A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.
Taylor EN; Timko C; Binswanger IA; Harris AHS; Stimmel M; Smelson D; Finlay AK
Subst Abus; 2022; 43(1):556-563. PubMed ID: 34586978
[No Abstract] [Full Text] [Related]
23. Are x-waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x-waiver trainings.
Gordon AJ; Kenny M; Dungan M; Gustavson AM; Kelley AT; Jones AL; Hawkins E; Frank JW; Danner A; Liberto J; Hagedorn H
Am J Addict; 2022 Mar; 31(2):152-158. PubMed ID: 35118756
[TBL] [Abstract][Full Text] [Related]
24. Expanding Access to Medications for Opioid Use Disorder: Program and Policy Approaches from Outside the Veterans Health Administration.
Priest KC; McCarty D; Lovejoy TI
J Gen Intern Med; 2020 Dec; 35(Suppl 3):886-890. PubMed ID: 33145685
[TBL] [Abstract][Full Text] [Related]
25. Barriers and facilitators to office-based opioid agonist therapy prescribing and effective interventions to increase provider prescribing: protocol for a systematic review.
Nixon LL; Marlinga JC; Hayden KA; Mrklas KJ
Syst Rev; 2019 Jul; 8(1):186. PubMed ID: 31345258
[TBL] [Abstract][Full Text] [Related]
26. Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis.
Priest KC; King CA; Englander H; Lovejoy TI; McCarty D
Subst Abus; 2022; 43(1):1251-1259. PubMed ID: 35670778
[No Abstract] [Full Text] [Related]
27. Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study.
Carter J; Li Z; Chen H; Greiner M; Bush C; Bhattacharya D; Poley S; Sachdeva N; Crowder JC; Feigal J
Addict Sci Clin Pract; 2022 Nov; 17(1):60. PubMed ID: 36335381
[TBL] [Abstract][Full Text] [Related]
28. Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022.
Meyerson BE; Treiber D; Brady BR; Newgass K; Bondurant K; Bentele KG; Samorano S; Arredondo C; Stavros N
J Subst Use Addict Treat; 2024 May; 160():209306. PubMed ID: 38296033
[TBL] [Abstract][Full Text] [Related]
29. Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives.
Bergman AA; Oberman RS; Taylor SL; Kranke B; Chang ET
J Gen Intern Med; 2024 Apr; ():. PubMed ID: 38587730
[TBL] [Abstract][Full Text] [Related]
30. Effects of Bundling Medication for Opioid Use Disorder With an mHealth Intervention Targeting Addiction: A Randomized Clinical Trial.
Gustafson DH; Landucci G; Vjorn OJ; Gicquelais RE; Goldberg SB; Johnston DC; Curtin JJ; Bailey GL; Shah DV; Pe-Romashko K; Gustafson DH
Am J Psychiatry; 2024 Feb; 181(2):115-124. PubMed ID: 37789744
[TBL] [Abstract][Full Text] [Related]
31. Empowering Psychiatric Mental Health Nurse Practitioners to Expand Treatment Opportunities for Veterans With Opioid Use Disorder.
Jones J; Tierney M; Jacobs G; Chien SY; Mallisham S
J Addict Nurs; 2020; 31(4):261-268. PubMed ID: 33264198
[TBL] [Abstract][Full Text] [Related]
32. Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs.
Winograd RP; Wood CA; Stringfellow EJ; Presnall N; Duello A; Horn P; Rudder T
J Subst Abuse Treat; 2020 Jan; 108():55-64. PubMed ID: 31277891
[TBL] [Abstract][Full Text] [Related]
33. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
Haffajee RL; Andraka-Christou B; Attermann J; Cupito A; Buche J; Beck AJ
Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):69. PubMed ID: 32928272
[TBL] [Abstract][Full Text] [Related]
34. Availability of Medications for Opioid Use Disorder in Community Mental Health Facilities.
Cantor J; Griffin BA; Levitan B; Mendon-Plasek SJ; Stein BD; Hunter SB; Ober AJ
JAMA Netw Open; 2024 Jun; 7(6):e2417545. PubMed ID: 38888921
[TBL] [Abstract][Full Text] [Related]
35. Expanding access to medications for opioid use disorder through locally-initiated implementation.
Wyse JJ; Mackey K; Lovejoy TI; Kansagara D; Tuepker A; Gordon AJ; Todd Korthuis P; Herreid-O'Neill A; Williams B; Morasco BJ
Addict Sci Clin Pract; 2022 Jun; 17(1):32. PubMed ID: 35725648
[TBL] [Abstract][Full Text] [Related]
36. Implementation of an office-based addiction treatment model for Medicaid enrollees: A mixed methods study.
Treitler P; Enich M; Bowden C; Mahone A; Lloyd J; Crystal S
J Subst Use Addict Treat; 2024 Jan; 156():209212. PubMed ID: 37935350
[TBL] [Abstract][Full Text] [Related]
37. Staff Attitudes toward Buprenorphine before and after Implementation of an Office-Based Opioid Treatment Program in an Urban Teaching Clinic.
James JR; Marolf M; Klein JW; Blalock KL; Merrill JO; Tsui JI
Subst Use Misuse; 2021; 56(11):1569-1575. PubMed ID: 34282999
[TBL] [Abstract][Full Text] [Related]
38. Adaptations to Opioid Use Disorder Care During the COVID-19 Pandemic: A National Survey of Prescribers.
Sung ML; Black AC; Blevins D; Henry BF; Cates-Wessel K; Dawes MA; Drexler K; Hagle H; Molfenter T; Levin FR; Becker WC; Edelman EJ
J Addict Med; 2022 Sep-Oct 01; 16(5):505-513. PubMed ID: 35020698
[TBL] [Abstract][Full Text] [Related]
39. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
Mauro PM; Gutkind S; Annunziato EM; Samples H
JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
[TBL] [Abstract][Full Text] [Related]
40. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
